Epikast

New York, United States

Epikast provides technology-enabled commercial and clinical services for the biopharmaceutical industry.

$2.2M raised

Jan 2026

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Epikast raised?

Epikast has raised $2.2M in total funding. The most recent round was Series B. The last funding was announced in January 2026.

Who are Epikast's investors?

Epikast's investors include EcoR1 Capital, Kos Biotechnology Partners.

Where is Epikast headquartered?

Epikast is headquartered in New York, United States.

What does Epikast do?

Epikast provides technology-enabled commercial and clinical services for the biopharmaceutical industry.

What stage is Epikast at?

Epikast is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 30, 2026.

MLA

"Epikast — Funding & Investors." VCBacked, January 30, 2026, https://www.vcbacked.co/company/epikast. Accessed July 4, 2026.

APA

VCBacked. (2026). Epikast — Funding & Investors. Retrieved July 4, 2026, from https://www.vcbacked.co/company/epikast

Wikipedia (cite web)

{{cite web |title=Epikast — Funding & Investors |url=https://www.vcbacked.co/company/epikast |website=VCBacked |access-date=July 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 30, 2026.